Opportunity Information: Apply for W81XWH 21 KCRP IDA
The FY21 DoD Kidney Cancer Research Program (KCRP) Idea Development Award is a research funding opportunity designed to push kidney cancer science forward through genuinely innovative, high-impact projects that align with the program's long-term vision of eliminating kidney cancer. It is aimed at supporting new ideas and bold approaches that are still grounded in solid evidence, with proposals expected to present a clear, testable hypothesis backed by a strong scientific rationale and an organized, realistic research plan. The program places a heavy emphasis on the quality and credibility of the proposed research approach, including whether the applicant team demonstrates deep understanding of kidney cancer biology and clinical challenges, and whether the project is positioned to produce outcomes that meaningfully advance the field rather than small, incremental gains.
A central theme of this award is that creativity must be paired with rigor. Applications are expected to lay out feasible experimental designs, clearly explain how goals will be met within the period of performance, and show that necessary resources are available, with documentation to support access to key infrastructure, cohorts, datasets, or specialized technologies. Strong applications are also expected to anticipate practical issues by identifying likely problems and pitfalls and proposing alternate approaches. When applicable, proposals should include a statistical analysis plan and power analysis to justify study design decisions and sample sizes. Preliminary data are required for submission, but they do not have to be kidney cancer-specific. The program allows preliminary support from a PI's or collaborator's prior work, whether unpublished or published, and relevant published literature can also help support feasibility and rationale.
Innovation is treated as a defining requirement rather than a bonus. The award is meant for research that introduces new paradigms, challenges existing ones, or reframes persistent problems in kidney cancer from new angles. High-risk/high-reward concepts are welcome, as long as the application makes a convincing case that success would translate into substantial impact on kidney cancer research directions, patient care, and/or quality of life. By design, projects that are expected to produce only incremental progress are not considered responsive to the spirit of this mechanism. Impact is evaluated in terms of whether the work tackles a central, critical issue in kidney cancer research or clinical care, and whether successful results would significantly advance methods or concepts within one or more FY21 KCRP Focus Areas.
The opportunity is open to both Established Investigators (EIs) and Early-Career Investigators (ECIs) serving as Principal Investigator (PI), and the program specifically signals interest in funding one or more highly meritorious applications led by an ECI. Personnel and team strength are treated as a crucial element of the application. Investigators are expected to demonstrate kidney cancer expertise through the PI's track record, the assembled research team, and/or documented collaborations. An EI is defined as an independent investigator at or above Assistant Professor (or equivalent) who is 10 years or more from completion of a terminal degree, with kidney cancer experience evidenced by publications and funding. An ECI is defined as an independent investigator at the Assistant Professor, Instructor, or Assistant Research Professor level (or equivalent) who is less than 10 years from their terminal degree at the time of the submission deadline, with specific allowances for excluding time in medical residency or family medical leave (but not postdoctoral time). Postdoctoral fellows are explicitly not eligible for ECI designation. For ECIs, the application must also show institutional commitment beyond money, such as protected research time, independent lab space, and collaboration opportunities, and it must include a required Career Development Plan and identify a Career Guide.
The Career Guide requirement is specific and structured. The ECI must designate a Career Guide who will provide career guidance and support in the context of the project. This individual must be at or above the Associate Professor level (or equivalent), must have a demonstrated record of kidney cancer research productivity and/or intellectual property and funding, and must provide a letter of support. In review, ECIs are assessed using different personnel criteria than established investigators, reflecting the program's intent to support strong early-stage independent researchers while still requiring a clear demonstration that the team can execute the proposed research.
In terms of what kinds of projects fit, the announcement highlights several appropriate scopes. Across all applications, the program supports innovative, high-risk/high-reward and/or preclinical research that is supported by preliminary and/or published data. Two special options allow for larger budgets when justified by added complexity and resource demands. The Early Detection Studies Option supports basic or preclinical work focused on biomarkers, improved imaging, and/or new technologies that could change how kidney cancer is detected earlier, and it allows higher funding in recognition that early detection research can require human subjects and/or human biospecimens. The Population Science and Prevention Studies Option supports preclinical population-based research, epidemiology, or public health work that is backed by substantial preliminary or published data and that strongly validates a path toward clinical translation in a well-defined kidney cancer context; this option also allows higher funding with compelling justification, again acknowledging the resource needs that often come with human subjects or biospecimen use. Use of data and/or biospecimens from active-duty Service Members and/or Veterans is encouraged, reflecting the program's military relevance. Human subjects research and research with human anatomical substances are permitted, but clinical trials are not allowed under this opportunity. Across all proposals, relevance is required to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public.
Awards under this program are issued as assistance agreements, meaning they may be made either as grants or cooperative agreements depending on anticipated DoD involvement. If no substantial involvement by the funding agency is expected, the award is typically a grant; if substantial involvement is anticipated, the award will be a cooperative agreement and will spell out the nature of that involvement, which could include collaboration, participation, or intervention during performance. The funding opportunity also points applicants to recommendations from the congressionally mandated Metastatic Cancer Task Force, encouraging proposals that address those recommendations as long as they fit within the announcement's limits and FY21 KCRP priorities. The program strongly encourages collaborations between military or Veteran institutions and non-military institutions to leverage complementary strengths such as infrastructure and access to unique clinical populations.
From a budgeting standpoint, the anticipated direct cost cap for the standard Idea Development Award is up to $600,000 for the entire period of performance. Under the Early Detection Studies Option, the cap increases to $650,000 in direct costs, and under the Population Science and Prevention Studies Option the cap can be as high as $2,000,000 in direct costs, reflecting the larger scale often required for those study types. The DoD planned to allocate approximately $15.76 million total to fund about 14 awards, with actual funding dependent on federal fund availability, the number of applications received, and the outcome of scientific peer review and programmatic review. The opportunity was released by the Department of Defense (U.S. Army Medical Research Acquisition Activity) under Funding Opportunity Number W81XWH-21-KCRP-IDA, with an original application closing date of October 5, 2021, and awards expected to be made no later than September 30, 2022. Funds were anticipated to be FY21 appropriations, available for use until they expire on September 30, 2027.Apply for W81XWH 21 KCRP IDA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Idea Development Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Apr 23, 2021.
- Applicants must submit their applications by Oct 05, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 14 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FY21 DoD Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) FAQs
1. What is the FY21 DoD KCRP Idea Development Award (IDA)?
The FY21 DoD Kidney Cancer Research Program (KCRP) Idea Development Award is a research funding opportunity intended to move kidney cancer science forward through genuinely innovative, high-impact projects aligned with the program's long-term vision of eliminating kidney cancer.
2. What kind of research is this award trying to support?
This mechanism supports bold, creative research concepts that are still backed by solid evidence, a clear and testable hypothesis, strong scientific rationale, and a realistic research plan. The program emphasizes projects positioned to create meaningful advances rather than small, incremental gains.
3. Is innovation optional or required for this award?
Innovation is treated as a defining requirement rather than a bonus. The award is intended for research that introduces new paradigms, challenges existing ones, or reframes persistent kidney cancer problems in new ways. Projects expected to yield only incremental progress are not responsive to the intent of this mechanism.
4. How does the program define "impact" for applications?
Impact is evaluated based on whether the proposed work tackles a central, critical issue in kidney cancer research or clinical care, and whether success would significantly advance methods or concepts within one or more FY21 KCRP Focus Areas. The program also considers whether success could substantially influence research directions, patient care, and/or quality of life.
5. Are high-risk/high-reward ideas allowed?
Yes. High-risk/high-reward concepts are welcomed, as long as the application convincingly argues that success would translate into substantial impact in kidney cancer research and/or patient outcomes.
6. What level of scientific rigor is expected in the research plan?
The program strongly emphasizes credibility and feasibility. Applications are expected to include feasible experimental designs, a clear explanation of how goals will be met during the period of performance, and evidence that the team has the expertise and resources needed to execute the work.
7. Do applicants need to address pitfalls and backup plans?
Yes. Strong applications are expected to anticipate likely problems and pitfalls and propose alternate approaches to keep the project on track.
8. Is a statistical analysis plan or power analysis required?
When applicable, proposals should include a statistical analysis plan and power analysis to justify study design decisions and sample sizes.
9. Is preliminary data required to apply?
Yes. Preliminary data are required for submission.
10. Does the preliminary data have to be kidney cancer-specific?
No. The preliminary data do not have to be kidney cancer-specific. The program allows preliminary support from the PI's or collaborators' prior work (published or unpublished), and relevant published literature may also be used to support feasibility and scientific rationale.
11. Who is eligible to serve as Principal Investigator (PI)?
The opportunity is open to both Established Investigators (EIs) and Early-Career Investigators (ECIs) serving as PI.
12. Does the program encourage Early-Career Investigator (ECI) applications?
Yes. The program specifically signals interest in funding one or more highly meritorious applications led by an ECI.
13. How is an Established Investigator (EI) defined?
An Established Investigator is an independent investigator at or above Assistant Professor (or equivalent) who is 10 years or more from completion of a terminal degree. Kidney cancer experience is expected to be evidenced by publications and funding.
14. How is an Early-Career Investigator (ECI) defined?
An Early-Career Investigator is an independent investigator at the Assistant Professor, Instructor, or Assistant Research Professor level (or equivalent) who is less than 10 years from their terminal degree at the time of the submission deadline, with specific allowances for excluding time in medical residency or family medical leave (but not postdoctoral time).
15. Are postdoctoral fellows eligible to be considered ECIs under this award?
No. Postdoctoral fellows are explicitly not eligible for ECI designation.
16. What additional expectations apply to Early-Career Investigator (ECI) applications?
ECI applications must demonstrate institutional commitment beyond money (for example, protected research time, independent lab space, and collaboration opportunities). ECIs must also include a required Career Development Plan and identify a Career Guide.
17. What is a Career Guide and when is one required?
A Career Guide is required for ECI-led applications. The Career Guide provides career guidance and support in the context of the proposed project.
18. What qualifications must the Career Guide have?
The Career Guide must be at or above the Associate Professor level (or equivalent), must have a demonstrated record of kidney cancer research productivity and/or intellectual property and funding, and must provide a letter of support.
19. How important is the project team and kidney cancer expertise?
Personnel and team strength are treated as a crucial element of the application. Applicants are expected to demonstrate kidney cancer expertise through the PI's track record, the assembled team, and/or documented collaborations, along with a clear understanding of kidney cancer biology and clinical challenges.
20. What types of research projects are considered appropriate for this award?
The announcement describes the award as supporting innovative, high-risk/high-reward and/or preclinical research supported by preliminary and/or published data. It also offers two special options (Early Detection Studies; Population Science and Prevention Studies) for projects that justify greater complexity and resources.
21. What is the Early Detection Studies Option?
The Early Detection Studies Option supports basic or preclinical work focused on biomarkers, improved imaging, and/or new technologies that could change how kidney cancer is detected earlier. It allows a higher direct cost cap, recognizing that early detection research can require human subjects and/or human biospecimens.
22. What is the Population Science and Prevention Studies Option?
The Population Science and Prevention Studies Option supports preclinical population-based research, epidemiology, or public health work backed by substantial preliminary or published data, with a strong validation of a path toward clinical translation in a well-defined kidney cancer context. It allows a higher direct cost cap due to resource demands that can come with human subjects or biospecimen use.
23. Are human subjects research and human biospecimen research allowed?
Yes. Human subjects research and research with human anatomical substances are permitted.
24. Are clinical trials allowed under this funding opportunity?
No. Clinical trials are not allowed under this opportunity.
25. Is use of Service Member or Veteran data/biospecimens encouraged?
Yes. Use of data and/or biospecimens from active-duty Service Members and/or Veterans is encouraged as part of the program's military relevance.
26. Who must the research be relevant to?
Across proposals, relevance is required to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public.
27. Does the program encourage collaboration between military/Veteran and non-military institutions?
Yes. The program strongly encourages collaborations between military or Veteran institutions and non-military institutions to leverage complementary strengths such as infrastructure and access to unique clinical populations.
28. What type of award instrument will be used (grant vs. cooperative agreement)?
Awards are issued as assistance agreements and may be made as grants or cooperative agreements depending on anticipated DoD involvement.
29. What is the difference between a grant and a cooperative agreement for this opportunity?
If no substantial involvement by the funding agency is expected, the award is typically a grant. If substantial involvement is anticipated, the award will be a cooperative agreement and will describe the nature of DoD involvement, which could include collaboration, participation, or intervention during performance.
30. What is the direct cost cap for the standard Idea Development Award?
The anticipated direct cost cap for the standard Idea Development Award is up to $600,000 for the entire period of performance.
31. What is the direct cost cap for the Early Detection Studies Option?
Under the Early Detection Studies Option, the direct cost cap increases to $650,000 for the entire period of performance.
32. What is the direct cost cap for the Population Science and Prevention Studies Option?
Under the Population Science and Prevention Studies Option, the direct cost cap can be as high as $2,000,000 in direct costs for the entire period of performance, with compelling justification.
33. How much total funding did DoD plan to allocate and how many awards were expected?
The DoD planned to allocate approximately $15.76 million total to fund about 14 awards, with actual funding dependent on federal fund availability, the number of applications received, and the outcomes of scientific peer review and programmatic review.
34. What is the Funding Opportunity Number for this announcement?
The Funding Opportunity Number is W81XWH-21-KCRP-IDA.
35. Which DoD office released this funding opportunity?
The opportunity was released by the Department of Defense (U.S. Army Medical Research Acquisition Activity).
36. What was the original application closing date?
The original application closing date was October 5, 2021.
37. When were awards expected to be made?
Awards were expected to be made no later than September 30, 2022.
38. How long were the FY21 funds expected to remain available?
Funds were anticipated to be FY21 appropriations and available for use until they expire on September 30, 2027.
39. What documentation or proof of resources does the program expect?
Applications are expected to show that necessary resources are available and to include documentation supporting access to key infrastructure, cohorts, datasets, and/or specialized technologies when relevant.
40. Does the program reference any external recommendations applicants can align with?
Yes. The funding opportunity points applicants to recommendations from the congressionally mandated Metastatic Cancer Task Force and encourages proposals that address those recommendations, as long as they remain within the announcement limits and FY21 KCRP priorities.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: DOD Neurofibromatosis, Early Investigator Research Award
Previous opportunity: Social and Economic Development Strategies -SEDS
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 21 KCRP IDA
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 21 KCRP IDA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Kidney Cancer, Concept Award Apply for W81XWH 21 KCRP CA Funding Number: W81XWH 21 KCRP CA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Kidney Cancer, Translational Research Partnership Award Apply for W81XWH 21 KCRP TRPA Funding Number: W81XWH 21 KCRP TRPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award Apply for W81XWH 21 KCRP PCFA Funding Number: W81XWH 21 KCRP PCFA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CyberCorps(R) Scholarship for Service Apply for 21 580 Funding Number: 21 580 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| DoD Breast Cancer, Breakthrough Award Levels 1 and 2 Apply for W81XWH 21 BCRP BTA12 2 Funding Number: W81XWH 21 BCRP BTA12 2 Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Breakthrough Award Level 4 Apply for W81XWH 21 BCRP BTA4 2 Funding Number: W81XWH 21 BCRP BTA4 2 Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Breakthrough Award Level 3 Apply for W81XWH 21 BCRP BTA3 2 Funding Number: W81XWH 21 BCRP BTA3 2 Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Innovator Award Apply for W81XWH 21 BCRP INNOV 2 Funding Number: W81XWH 21 BCRP INNOV 2 Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Transformative Breast Cancer Research Award Apply for W81XWH 21 BCRP TBCCA 2 Funding Number: W81XWH 21 BCRP TBCCA 2 Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Breast Cancer, Era of Hope Scholar Award Apply for W81XWH 21 BCRP EOHS 2 Funding Number: W81XWH 21 BCRP EOHS 2 Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Research and Development in Forensic Science for Criminal Justice Purposes, Fiscal Year 2021 Apply for O NIJ 2021 95001 Funding Number: O NIJ 2021 95001 Agency: Department of Justice, National Institute of Justice Category: Science and Technology and other Research and Development Funding Amount: $9,400,000 |
| Research to Reduce Trauma for Child Pornography Victims, Fiscal Year 2021 Apply for O NIJ 2021 97002 Funding Number: O NIJ 2021 97002 Agency: Department of Justice, National Institute of Justice Category: Science and Technology and other Research and Development Funding Amount: $1,500,000 |
| Forensic Technology Center of Excellence, Fiscal Year 2021 Apply for O NIJ 2021 97001 Funding Number: O NIJ 2021 97001 Agency: Department of Justice, National Institute of Justice Category: Science and Technology and other Research and Development Funding Amount: $4,500,000 |
| DoD Lupus, Transformative Vision Award Apply for W81XWH 21 LRP TVA Funding Number: W81XWH 21 LRP TVA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Lupus, Impact Award Apply for W81XWH 21 LRP IPA Funding Number: W81XWH 21 LRP IPA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Lupus, Idea Award Apply for W81XWH 21 LRP IA Funding Number: W81XWH 21 LRP IA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Fomenting research partnerships between the U.S. and the D.R. Apply for S DR860 21 NOFO 002 Funding Number: S DR860 21 NOFO 002 Agency: Department of State, U.S. Mission to the Dominican Republic Category: Science and Technology and other Research and Development Funding Amount: $25,000 |
| DOD Bone Marrow Failure, Idea Development Award Apply for W81XWH 21 BMFRP IDA Funding Number: W81XWH 21 BMFRP IDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD Bone Marrow Failure, Investigator-Initiated Research Award Apply for W81XWH 21 BMFRP IIRA Funding Number: W81XWH 21 BMFRP IIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Resilient & Intelligent NextG Systems Apply for 21 581 Funding Number: 21 581 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 21 KCRP IDA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.